Ashok A. Hajare

Microemulsion-Mediated Abiraterone Acetate Nanoparticles: Formulation and Optimization

The BCS Class IV drug abiraterone acetate (ABR) exhibits biopharmaceutical difficulties including polymorphism, poor solubility (< 0.5 µg/mL), variable permeability, and low oral bioavailability (<10 %, necessitating a large dose of 1000 mg/day). The primary goal of the current study is to produce solid lipid nanoparti...